AVEO Pharmaceuticals, Inc. – NASDAQ:AVEO

Financial Health
0
1
2
3
4
5
6
7
8
9

AVEO Pharmaceuticals stock price monthly change

+0.47%
month

AVEO Pharmaceuticals stock price quarterly change

+1.42%
quarter

AVEO Pharmaceuticals stock price yearly change

+322.54%
year

AVEO Pharmaceuticals key metrics

Market Cap
N/A
Enterprise value
480.55M
P/E
-17.88
EV/Sales
7.04
EV/EBITDA
-14.79
Price/Sales
7.61
Price/Book
18.00
PEG ratio
0.35
EPS
-1.17
Revenue
90.89M
EBITDA
-32.47M
Income
-40.52M
Revenue Q/Q
100.67%
Revenue Y/Y
255.97%
Profit margin
-42.6%
Oper. margin
-35.93%
Gross margin
83.14%
EBIT margin
-35.93%
EBITDA margin
-35.73%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

AVEO Pharmaceuticals stock price history

AVEO Pharmaceuticals stock forecast

AVEO Pharmaceuticals financial statements

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Profit margin
Dec 2021 14.22M -15.28M -107.47%
Mar 2022 20.92M -11.38M -54.43%
Jun 2022 25.30M -9.48M -37.48%
Sep 2022 30.44M -4.36M -14.33%
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Earnings per share (EPS)
2022-05-05 -0.25 -0.3
2022-08-04 -0.28 -0.24
2022-11-07 -0.18 -0.09
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Debt to assets
Dec 2021 105341000 59.47M 56.46%
Mar 2022 98215000 61.27M 62.39%
Jun 2022 98111000 67.52M 68.82%
Sep 2022 101233000 72.38M 71.51%
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Cash Flow
Dec 2021 -12.18M 8.36M 5.52M
Mar 2022 -8.21M 11.52M 0
Jun 2022 -2.45M -1.78M 561K
Sep 2022 194K 7M 36K

AVEO Pharmaceuticals alternative data

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Employee count
Aug 2023 114
Sep 2023 114
Oct 2023 114
Nov 2023 114
Dec 2023 114
Jan 2024 114
Feb 2024 114
Apr 2024 114
May 2024 114
Jun 2024 114
Jul 2024 114

AVEO Pharmaceuticals other data

41.09% -3.78%
of AVEO is owned by hedge funds
14.12M -1.29M
shares is hold by hedge funds

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Insider trades (number of shares)
Period Buy Sel
Aug 2021 2608 0
Sep 2021 15000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
BAILEY MICHAEL P director, officer.. Stock Option (right to buy) 164,525 $3.67 $603,807
Option
BAILEY MICHAEL P director, officer.. Stock Option (right to buy) 85,722 $5.6 $480,043
Option
BAILEY MICHAEL P director, officer.. Stock Option (right to buy) 26,499 $6.2 $164,294
Option
BAILEY MICHAEL P director, officer.. Common Stock 164,525 $3.67 $603,807
Option
BAILEY MICHAEL P director, officer.. Common Stock 85,722 $5.6 $480,043
Option
BAILEY MICHAEL P director, officer.. Common Stock 26,499 $6.2 $164,294
Purchase
BAILEY MICHAEL P director, officer.. Common Stock 15,000 $6.48 $97,200
Purchase
FERRARESSO MICHAEL
Common Stock 2,608 $5.75 $14,996
Purchase
GROWTH EQUITY OPPORTUNITIES FUND IV, LLC 10 percent owner
Common Stock 1,428,571 N/A N/A
Purchase
BASKETT FOREST 10 percent owner
Common Stock 1,428,571 $5.25 $7,499,998
Patent
Application
Filling date: 14 Apr 2022 Issue date: 28 Jul 2022
Application
Filling date: 7 Oct 2021 Issue date: 28 Jul 2022
Application
Filling date: 5 Nov 2019 Issue date: 6 Jan 2022
Application
Filling date: 13 Aug 2020 Issue date: 10 Jun 2021
Application
Filling date: 19 Mar 2020 Issue date: 8 Apr 2021
Application
Filling date: 29 Oct 2019 Issue date: 24 Sep 2020
Grant
Filling date: 8 Jan 2018 Issue date: 18 Aug 2020
Grant
Filling date: 20 Jul 2017 Issue date: 24 Mar 2020
Grant
Filling date: 2 Mar 2017 Issue date: 3 Dec 2019
Application
Filling date: 2 Nov 2018 Issue date: 26 Sep 2019
Thursday, 28 March 2024
globenewswire.com
Monday, 25 March 2024
globenewswire.com
Tuesday, 6 February 2024
globenewswire.com
Tuesday, 16 January 2024
globenewswire.com
Friday, 30 December 2022
Zacks Investment Research
Monday, 26 December 2022
Zacks Investment Research
Monday, 21 November 2022
Zacks Investment Research
Monday, 14 November 2022
Zacks Investment Research
Monday, 7 November 2022
Zacks Investment Research
Zacks Investment Research
Thursday, 27 October 2022
Zacks Investment Research
Friday, 21 October 2022
Zacks Investment Research
Wednesday, 19 October 2022
Pulse2
Tuesday, 18 October 2022
Schaeffers Research
Yahoo Finance
Investors Business Daily
InvestorPlace
Friday, 14 October 2022
Zacks Investment Research
Friday, 30 September 2022
Zacks Investment Research
Tuesday, 20 September 2022
Zacks Investment Research
Wednesday, 14 September 2022
Zacks Investment Research
Monday, 12 September 2022
Zacks Investment Research
Friday, 9 September 2022
Zacks Investment Research
Tuesday, 6 September 2022
Zacks Investment Research
Wednesday, 31 August 2022
GlobeNewsWire
Monday, 29 August 2022
Zacks Investment Research
Friday, 26 August 2022
Zacks Investment Research
Monday, 15 August 2022
Seeking Alpha
Friday, 12 August 2022
Zacks Investment Research
Tuesday, 9 August 2022
Zacks Investment Research
  • When is AVEO Pharmaceuticals's next earnings date?

    Unfortunately, AVEO Pharmaceuticals's (AVEO) next earnings date is currently unknown.

  • Does AVEO Pharmaceuticals pay dividends?

    No, AVEO Pharmaceuticals does not pay dividends.

  • What is AVEO Pharmaceuticals's stock symbol?

    AVEO Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AVEO".

  • What is AVEO Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of AVEO Pharmaceuticals?

    Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are AVEO Pharmaceuticals's key executives?

    AVEO Pharmaceuticals's management team includes the following people:

    • Mr. Michael P. Bailey Chief Executive Officer, Pres & Director(age: 60, pay: $1,080,000)
  • How many employees does AVEO Pharmaceuticals have?

    As Jul 2024, AVEO Pharmaceuticals employs 114 workers.

  • When AVEO Pharmaceuticals went public?

    AVEO Pharmaceuticals, Inc. is publicly traded company for more then 15 years since IPO on 12 Mar 2010.

  • What is AVEO Pharmaceuticals's official website?

    The official website for AVEO Pharmaceuticals is aveooncology.com.

  • Where are AVEO Pharmaceuticals's headquarters?

    AVEO Pharmaceuticals is headquartered at 30 Winter Street, Boston, MA.

  • How can i contact AVEO Pharmaceuticals?

    AVEO Pharmaceuticals's mailing address is 30 Winter Street, Boston, MA and company can be reached via phone at 857 400 0101.

AVEO Pharmaceuticals company profile:

AVEO Pharmaceuticals, Inc.

aveooncology.com
Exchange:

NASDAQ

Full time employees:

114

Industry:

Biotechnology

Sector:

Healthcare

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

30 Winter Street
Boston, MA 02108

CIK: 0001325879
ISIN: US0535883070
CUSIP: 053588307